Physician profile
Howland E Crosswell
NPI 1811943871
$14,371.14
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,317 · 2020: $32.36 · 2021: $2,003 · 2022: $5,898 · 2023: $795 · 2024: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $946 · Food and Beverage: $810 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $946.00 |
| Food and Beverage | $810.43 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $365.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $3,675.91 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $3,664.56 | 2019-2024 | Zepzelca |
| Seagen INC. | $2,170.00 | 2022 | |
| Pharmacosmos Therapeutics INC. | $1,500.00 | 2021 | |
| Adaptive Biotechnologies Corporation | $1,263.97 | 2021-2024 | Clonoseq |
| E.R. Squibb & Sons, L.L.C. | $946.00 | 2024 | |
| Daiichi Sankyo INC. | $136.36 | 2019 | |
| Gilead Sciences, INC. | $121.68 | 2022-2023 | |
| Kyowa Kirin, INC. | $118.02 | 2019 | |
| Mallinckrodt Enterprises LLC | $111.80 | 2019 | |
| Blueprint Medicines Corporation | $109.86 | 2024 | |
| Novartis Pharmaceuticals Corporation | $109.82 | 2019-2023 | |
| Amgen INC. | $100.68 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $50.37 | 2019-2023 | Keytruda |
| Eisai INC. | $44.05 | 2022-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $41.36 | 2019-2023 | Pomalyst, Opdualag |
| Astrazeneca Pharmaceuticals Lp | $29.63 | 2020-2023 | Calquence |
| Kite Pharma, INC. | $25.45 | 2020-2022 | |
| Novocure INC. | $25.00 | 2022 | |
| Glaxosmithkline, LLC. | $21.16 | 2023 | |
| Genzyme Corporation | $20.05 | 2019 | |
| Secura Bio, INC. | $15.06 | 2019 | |
| Astellas Pharma US INC | $12.72 | 2019 | |
| Exelixis INC. | $12.62 | 2022 | |
| Genentech USA, INC. | $11.92 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.87 | 2019 | |
| Janssen Biotech, INC. | $11.28 | 2019 | |
| Clovis Oncology, INC. | $9.94 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howland Crosswell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.